2994-9750

JCO Oncology Advances

American Society of Clinical Oncology

View prefix report (10.1200)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add license metadata to 176 records

License metadata tells indexers and readers how each article may be reused.

High impact176 DOIs
2

Add abstracts to 26 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact26 DOIs
3

Deposit reference lists for 4 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact4 DOIs

DOIs for this ISSN

Showing the top 5 of 176 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 State of Professional Well-Being, Satisfaction, and Career P… (10.1200/oa.24.00010)
License
34.04 22
2 Challenges and Opportunities in Targeting the Complex Pancre… (10.1200/oa-24-00050)
License
32.53 19
3 Real-World Utilization and Performance of Circulating Tumor… (10.1200/oa-24-00084)
License
26.98 11
4 Stereotactic Ablative Body Radiotherapy for Oligoprogressive… (10.1200/oa-25-00031)
License
26.98 11
5 Inavolisib-Based Triplet Therapy for <i>PIK3CA</… (10.1200/oa-25-00041)
Abstract License
23.86 2
6 Analysis of 20 Independently Performed Assays to Measure Hom… (10.1200/oa-24-00042)
License
22.58 7
7 Neoadjuvant Atezolizumab in Patients With Surgically Resecta… (10.1200/oa-24-00058)
License
22.58 7
8 Immune Checkpoint Blockade Therapies for Colorectal Cancer:… (10.1200/oa-24-00077)
License
22.58 7
9 Small Cell Lung Cancer: New Hope, New Challenges (10.1200/oa.0000000000000001)
License
22.58 7
10 Cancer of Unknown Primary Site: A New Era of Practice-Changi… (10.1200/oa-24-00041)
License
19.45 5
11 Toward Functional Biomarkers of Response to Neoadjuvant Onco… (10.1200/oa-24-00049)
License
19.45 5
12 Randomized Trial of Fixed-Dose Capecitabine Compared With St… (10.1200/oa-24-00068)
License
19.45 5
13 Differential Survival Among Patients With Cancer by COVID-19… (10.1200/oa-24-00034)
License
17.47 4
14 Phase II Study of Pexidartinib Plus Sirolimus in Unresectabl… (10.1200/oa-24-00083)
License
17.47 4
15 Phase II Study of Peri- and Post-Transplant Ruxolitinib for… (10.1200/oa-25-00020)
License
17.47 4
16 Impact of the COVID-19 Pandemic Mitigation Strategies on Can… (10.1200/oa-25-00021)
License
17.47 4
17 Gastric Adenocarcinoma in the United States: The Toll of Lat… (10.1200/oa-25-00063)
License
17.47 4
18 Age and Sex Affects the Frequency and Mutation Type of… (10.1200/oa.24.00027)
License
17.47 4
19 Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combinat… (10.1200/oa-24-00039)
License
15.05 3
20 Nivolumab in Patients With Advanced or Metastatic Malignanci… (10.1200/oa-24-00044)
License
15.05 3
21 Advancing Oncology Through Broad Access and Inclusive Scienc… (10.1200/oa-24-00060)
Abstract License
15.05 1
22 Efbemalenograstim Alfa, a Long-Acting Granulocyte Colony-Sti… (10.1200/oa-24-00074)
License
15.05 3
23 Safety and Efficacy of Antiangiogenesis Agents in Patients W… (10.1200/oa-24-00089)
Abstract License
15.05 1
24 Increasing Cervical Cancer Rates Among Women Age 35-54 Years… (10.1200/oa-24-00101)
License
15.05 3
25 More Frequent than Annual Administration of COVID-19 Vaccina… (10.1200/oa-24-00107)
Abstract License
15.05 1
26 SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versu… (10.1200/oa-25-00037)
Abstract License
15.05 1
27 Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and… (10.1200/oa-25-00099)
Abstract License
15.05 1
28 Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in… (10.1200/oa-25-00113)
Abstract License
15.05 1
29 NEO-RT Organ Preservation Trial for Early Rectal Cancer: CCT… (10.1200/oa-25-00176)
Abstract License
15.05 1
30 Strengthening Supportive Care: Leveraging the Expanding Role… (10.1200/oa-25-00180)
Abstract License
15.05 1
31 Translational Implications of Microbiome Testing Methodologi… (10.1200/oa-25-00194)
License
15.05 3
32 Examining Racial Disparities in the Association Between Food… (10.1200/oa.24.00005)
License
15.05 3
33 Disparities in Utilization of Immune Checkpoint Inhibitor Th… (10.1200/oa.24.00008)
License
15.05 3
34 Short-Course Adjuvant Vaginal Cuff Brachytherapy in Early En… (10.1200/oa.24.00014)
License
15.05 3
35 Molecular Characterization and Clinical Outcomes of Pancreat… (10.1200/oa-24-00032)
License
11.93 2
36 CD40 Ligand Blockade for Prevention of Graft-Versus-Host Dis… (10.1200/oa-24-00040)
License
11.93 2
37 Considerations in Neoadjuvant Therapy Implementation in T3 a… (10.1200/oa-24-00071)
License
11.93 2
38 Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in… (10.1200/oa-24-00086)
License
11.93 2
39 Patient-Reported Outcomes During Pelvic Radiation Therapy: A… (10.1200/oa-24-00088)
License
11.93 2
40 ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapse… (10.1200/oa-24-00095)
License
11.93 2
41 Cost-Related Health Care Delays in Adolescents and Young Adu… (10.1200/oa-24-00097)
License
11.93 2
42 Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastati… (10.1200/oa-24-00102)
License
11.93 2
43 Innovations Versus Health Equity? Effects of Cancer Treatmen… (10.1200/oa-25-00026)
License
11.93 2
44 Low-Dose Total Skin Electron Beam Radiotherapy in Stage IB-I… (10.1200/oa-25-00065)
License
11.93 2
45 Impact of Food and Drug Administration Project Optimus Guida… (10.1200/oa-25-00084)
License
11.93 2
46 Functional Impact of Transoral Surgery and Risk-Based Adjuva… (10.1200/oa-25-00092)
License
11.93 2
47 Outcomes of Patients With Rare Cancers Treated With Combinat… (10.1200/oa-25-00110)
License
11.93 2
48 Phase I Clinical Trial Evaluating Safety, Tolerability, and… (10.1200/oa-25-00114)
License
11.93 2
49 Novel Blood-Based Liquid Biopsy Approaches in Hepatocellular… (10.1200/oa-25-00132)
License
11.93 2
50 Maintenance Capecitabine Plus Ramucirumab After First-Line C… (10.1200/oa-24-00073)
License
7.53 1